Chan Whiting
Plus aucun poste en cours
Profil
Chan Whiting worked as the Director & Head-Immune Monitoring at Aduro BioTech, Inc. and as the Senior Vice President-Research & Development at Tempest Therapeutics, Inc. before obtaining an undergraduate and doctorate degree from the University of California, Los Angeles.
Anciens postes connus de Chan Whiting
| Sociétés | Poste | Fin |
|---|---|---|
| TEMPEST THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/09/2021 |
| CHINOOK THERAPEUTICS, INC. | Directeur/Membre du Conseil | - |
Formation de Chan Whiting
| University of California, Los Angeles | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TEMPEST THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
